2 weeks Ago By Defense World Staff
Townsquare Capital LLC reduced its stake in shares of Hologic, Inc. ( NASDAQ:HOLX – Free Report ) by 81.1% during the 4th quarter, according to its most recent 13F filing with the SEC.
The institutional investor owned 6,470 shares of the medical equipment provider’s stock after selling 27,851 shares during the period. Townsquare Capital LLC’s holdings in Hologic were worth $466,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also made changes to their positions in the company.
General Partner Inc. purchased a new stake in Hologic during the fourth quarter worth about $26,000. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.
3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.
8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Hologic by 36.
9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 159 shares during the period. Finally, Smithfield Trust Co increased its stake in Hologic by 160.
0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 400 shares in the last quarter. 94.
73% of the stock is owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth A number of analysts have commented on the company. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.
00 to $75.00 in a research report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th.
Stephens restated an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Citigroup reduced their price target on shares of Hologic from $80.
00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Morgan Stanley lowered their price target on shares of Hologic from $84.
00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock.
Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $84.62. Hologic Price Performance Shares of NASDAQ:HOLX opened at $57.
56 on Monday. The company has a market cap of $12.92 billion, a P/E ratio of 18.
16, a P/E/G ratio of 2.14 and a beta of 0.82.
The business has a fifty day simple moving average of $61.58 and a 200-day simple moving average of $70.70.
Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.
67. The company has a quick ratio of 2.78, a current ratio of 3.
49 and a debt-to-equity ratio of 0.52. Hologic ( NASDAQ:HOLX – Get Free Report ) last posted its quarterly earnings results on Wednesday, February 5th.
The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.
01. Hologic had a return on equity of 19.72% and a net margin of 18.
42%. Equities research analysts forecast that Hologic, Inc. will post 4.
28 EPS for the current year. Hologic Profile ( Free Report ) Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. Featured Stories Five stocks we like better than Hologic How to invest in marijuana stocks in 7 steps With a 60%+ Upside, There’s Plenty to Love About Lovesac When to Sell a Stock for Profit or Loss J.B.
Hunt Transport Overcorrects Into a Buying Opportunity What is the NASDAQ Stock Exchange? AppLovin: Can Record Profits Overcome Market Skepticism? Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. ( NASDAQ:HOLX – Free Report ).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter ..
